Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response With Imatinib

NCT04043676 is registered in ClinicalTrials.gov with Fundación Teófilo Hernando, Spain as lead sponsor.

NCT NCT04043676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04043676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response With Imatinib
Lead sponsor
Fundación Teófilo Hernando, Spain
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2019
Completion date
April 30, 2023
Enrollment
40 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia